查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Adalimumab的全球市場 (～2028年):類型·產品類型·治療領域·流通管道·終端用戶·各地區的產業規模·佔有率·趨勢·機會·預測
市場調查報告書
商品編碼
1174488

Adalimumab的全球市場 (～2028年):類型·產品類型·治療領域·流通管道·終端用戶·各地區的產業規模·佔有率·趨勢·機會·預測

Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product Type, By Therapeutic Area, By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2028
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球Adalimumab的市場從2024年到2028年將達成大幅成長。

關節炎患病率的上升和大量臨床試驗的實施正在推動市場的增長。保險報銷的範圍和明確的監管指南預計也將在 2028 年之前刺激市場增長。另一方面，重磅藥物的專利到期和副作用預計將抑制市場增長。

本報告提供全球Adalimumab的市場調查，彙整市場概要，市場規模及市場佔有率的轉變·預測，各種區分·地區/各主要國家的詳細分析，市場的各種影響因素的分析，競爭環境，主要企業簡介等資訊。

目錄

第1章 產品概要

第2章 調查手法

第3章 摘要整理

第4章 VOC (客戶的迴響)

第5章 Adalimumab的藥效學的概要

  • 作用機制
  • 吸收
  • 流通數量
  • 排泄途徑
  • 半衰期
  • clearance
  • 毒性

第6章 臨床試驗

  • 進行中的臨床試驗
  • 達成臨床試驗
  • 中止臨床試驗
  • 臨床試驗分析

第7章 專利分析

第8章 全球Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型 (生技藥品·生物相似藥)
    • 各產品類型 (品牌·非專利)
    • 各治療領域 (類風濕性關節炎·乾癬性關節炎·乾癬·克隆氏症·其他)
    • 流通管道 (醫院藥局·零售藥局·線上藥局·其他)
    • 各終端用戶 (醫院及診療所·居家醫療·其他)
    • 各企業 (2022年)
    • 各地區
  • 產品市場地圖

第9章 北美的Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型
    • 各產品類型
    • 各治療領域
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第10章 歐洲的Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型
    • 各產品類型
    • 各治療領域
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第11章 亞太地區的Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型
    • 各產品類型
    • 各治療領域
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第12章 南美的Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型
    • 各產品類型
    • 各治療領域
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第13章 中東·非洲的Adalimumab市場展望

  • 市場規模·預測
  • 市場佔有率·預測
    • 各類型
    • 各產品類型
    • 各治療領域
    • 各流通管道
    • 各終端用戶
    • 各國
  • 各國分析

第14章 市場動態

  • 促進因素
  • 課題

第15章 市場趨勢·展開

第16章 競爭情形

  • Abbvie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

第17章 策略性建議

第18章 關於本公司·免責聲明

簡介目錄
Product Code: 4996

Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα. Adalimumab are currently being marketed in over 60 countries around the world.

Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.

Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.

Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.

Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.

Objective of the Study

  • To analyse and forecast the market size of global adalimumab market.
  • To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
  • To identify drivers and challenges for global adalimumab market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
  • To identify and analyse the profile of leading players operating in the global adalimumab market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to adalimumab
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Adalimumab Market, By Type:

  • Biologics
  • Biosimilar

Global Adalimumab Market, By Product Type:

  • Branded
  • Generics

Global Adalimumab Market, By Therapeutic Area:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn's Disease
  • Others

Global Adalimumab Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Global Adalimumab Market, By End User:

  • Hospitals & Clinics
  • Home Healthcare
  • Others

Global Adalimumab Market, By Region:

  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • North America
    • United States
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global adalimumab market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Adalimumab Demand, By Therapeutic Area
  • 4.2. Adalimumab Demand, By Region
  • 4.3. Adalimumab Demand, By Gender
  • 4.4. Adalimumab Demand, By Patient Population
  • 4.5. Commonly Observed Side-Effects
  • 4.6. Brand Awareness

5. Pharmacodynamic Overview of Adalimumab

  • 5.1. Mechanism of Action
  • 5.2. Absorption
  • 5.3. Volume of Distribution
  • 5.4. Route of Elimination
  • 5.5. Half Life
  • 5.6. Clearance
  • 5.7. Toxicity

6. Clinical Trials

  • 6.1. Ongoing Clinical Trials
  • 6.2. Completed Clinical Trials
  • 6.3. Terminated Clinical Trials
  • 6.4. Clinical Trial Analysis

7. Patent Analysis

  • 7.1. Patent Granted
  • 7.2. Patent Applications Filed

8. Global Adalimumab Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Biologics v/s Biosimilars)
    • 8.2.2. By Product Type (Branded v/s Generics)
    • 8.2.3. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
    • 8.2.4. Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
    • 8.2.5. By End User (Hospitals & Clinics, Home Healthcare, Others)
    • 8.2.6. By Company (2022)
    • 8.2.7. By Region
  • 8.3. Product Market Map

9. North America Adalimumab Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product Type
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Distribution Channel
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Adalimumab Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Therapeutic Area
        • 9.3.1.2.4. By Distribution Channel
        • 9.3.1.2.5. By End User
    • 9.3.2. Mexico Adalimumab Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Therapeutic Area
        • 9.3.2.2.4. By Distribution Channel
        • 9.3.2.2.5. By End User
    • 9.3.3. Canada Adalimumab Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Therapeutic Area
        • 9.3.3.2.4. By Distribution Channel
        • 9.3.3.2.5. By End User

10. Europe Adalimumab Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product Type
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Distribution Channel
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Adalimumab Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Therapeutic Area
        • 10.3.1.2.4. By Distribution Channel
        • 10.3.1.2.5. By End User
    • 10.3.2. Germany Adalimumab Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Therapeutic Area
        • 10.3.2.2.4. By Distribution Channel
        • 10.3.2.2.5. By End User
    • 10.3.3. United Kingdom Adalimumab Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Therapeutic Area
        • 10.3.3.2.4. By Distribution Channel
        • 10.3.3.2.5. By End User
    • 10.3.4. Italy Adalimumab Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Product Type
        • 10.3.4.2.3. By Therapeutic Area
        • 10.3.4.2.4. By Distribution Channel
        • 10.3.4.2.5. By End User
    • 10.3.5. Spain Adalimumab Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Product Type
        • 10.3.5.2.3. By Therapeutic Area
        • 10.3.5.2.4. By Distribution Channel
        • 10.3.5.2.5. By End User

11. Asia-Pacific Adalimumab Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Product Type
    • 11.2.3. By Therapeutic Area
    • 11.2.4. By Distribution Channel
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Adalimumab Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Therapeutic Area
        • 11.3.1.2.4. By Distribution Channel
        • 11.3.1.2.5. By End User
    • 11.3.2. India Adalimumab Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Therapeutic Area
        • 11.3.2.2.4. By Distribution Channel
        • 11.3.2.2.5. By End User
    • 11.3.3. South Korea Adalimumab Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Transgenic Crop
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Japan Adalimumab Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Type
        • 11.3.4.2.2. By Product Type
        • 11.3.4.2.3. By Therapeutic Area
        • 11.3.4.2.4. By Distribution Channel
        • 11.3.4.2.5. By End User
    • 11.3.5. Australia Adalimumab Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Type
        • 11.3.5.2.2. By Product Type
        • 11.3.5.2.3. By Therapeutic Area
        • 11.3.5.2.4. By Distribution Channel
        • 11.3.5.2.5. By End User

12. South America Adalimumab Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Type
    • 12.2.2. By Product Type
    • 12.2.3. By Therapeutic Area
    • 12.2.4. By Distribution Channel
    • 12.2.5. By End User
    • 12.2.6. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Adalimumab Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Type
        • 12.3.1.2.2. By Product Type
        • 12.3.1.2.3. By Therapeutic Area
        • 12.3.1.2.4. By Distribution Channel
        • 12.3.1.2.5. By End User
    • 12.3.2. Argentina Adalimumab Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Type
        • 12.3.2.2.2. By Product Type
        • 12.3.2.2.3. By Therapeutic Area
        • 12.3.2.2.4. By Distribution Channel
        • 12.3.2.2.5. By End User
    • 12.3.3. Colombia Adalimumab Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Type
        • 12.3.3.2.2. By Product Type
        • 12.3.3.2.3. By Therapeutic Area
        • 12.3.3.2.4. By Distribution Channel
        • 12.3.3.2.5. By End User

13. Middle East and Africa Adalimumab Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value & Volume
  • 13.2. Market Share & Forecast
    • 13.2.1. By Type
    • 13.2.2. By Product Type
    • 13.2.3. By Therapeutic Area
    • 13.2.4. By Distribution Channel
    • 13.2.5. By End User
    • 13.2.6. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Adalimumab Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Type
        • 13.3.1.2.2. By Product Type
        • 13.3.1.2.3. By Therapeutic Area
        • 13.3.1.2.4. By Distribution Channel
        • 13.3.1.2.5. By End User
    • 13.3.2. Saudi Arabia Adalimumab Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Type
        • 13.3.2.2.2. By Product Type
        • 13.3.2.2.3. By Therapeutic Area
        • 13.3.2.2.4. By Distribution Channel
        • 13.3.2.2.5. By End User
    • 13.3.3. UAE Adalimumab Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Type
        • 13.3.3.2.2. By Product Type
        • 13.3.3.2.3. By Therapeutic Area
        • 13.3.3.2.4. By Distribution Channel
        • 13.3.3.2.5. By End User

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. Competitive Landscape

  • 16.1. Abbvie Inc.
  • 16.2. Pfizer, Inc.
  • 16.3. Amgen Inc.
  • 16.4. Novartis AG
  • 16.5. Torrent Pharmaceuticals Ltd.
  • 16.6. Cadila Healthcare Limited
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Mylan N.V.
  • 16.9. Hetero Biopharma Ltd
  • 16.10. Samsung Bioepis Co Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer